Skip to main content

Control of the Ebola Oubreak by both innovative Ultrasensitive Detection of EBOV and therapy

Objective

IF-EBOLA has been strategically designed to efficiently respond to critical needs required to control Ebola outbreak from spreading and prepare a therapeutic approach to save lives. The work involves two of the main EVD outbreak sites, Sierra Leone and Liberia. MDs, public health authorities and virus experts working on site, under ethical regulatory rules, will extend their collaboration to companies and institutions to form a consortium of outstanding complementary partners, sharing their innovative technological approaches for a common goal.
The main goal of our project is to contribute to provide innovative ultrasensitive diagnostics and therapeutic approaches for an early and accurate diagnostic for an early therapeutic treatment to control the epidemic and safe lives.

We have been obligated to modify and extend for one year our initial two-year period IF-EBOLA action program due to both major foreseen and unforeseen changes produced during this “non-emergency” period: consisting mainly now in 3 main actions: (i) Preclinical validation of the therapeutic equine anti-Ebola antibodies; (ii) Clinical validation of the ultrasensitive detection (iii) homeostasis (“pathology”) profiling of patients and survivors.
Originally (“emergency period”) IF-EBOLA included 2 phases: (I) a phase of preparation including, ethical authorizations, antibody production, technical and field organization as well as the beginning a follow-up of the homeostatic profile of contacts early-EBOV diagnosed and self-cured convalescent individuals in the absence of existing treatment, (with an ultrasensitive detection method of pernicious microorganisms, from the EC USDEP project qualified as a European success story “USDEP” project in 2010 by the EC-Project Officer) and (II) phase of a clinical study using a wide validated approach revisited with an innovative concept (strongly supported EC/EMA-WHO), we propose to carry out an experimental passive-immune therapy based on neutralizing capacity of horse anti-EBOV polyclonal F(ab’)2 on early-diagnosed patients to impact and reduce their pre-existing viremia, their mortality, the evolution of their homeostasis profile, during and after this treatment (once patients become convalescents). The homeostasis status evolution will help to generate high quality scientific data to understand the EVD, the effect of this therapy and cure parameters characterized at 3 different levels: immune (transcriptomes, NGS, metagenomics); infectious (other than EBOV, DNA arrays), and EBOV diversity (sequencing and metagenomics).

Field of science

  • /medical and health sciences/basic medicine/physiology/homeostasis
  • /medical and health sciences/health sciences/public and environmental health/epidemics prevention/immunisation
  • /natural sciences/biological sciences/microbiology/virology
  • /medical and health sciences/basic medicine/pharmacology and pharmacy/pharmaceutical drug/vaccines
  • /natural sciences/biological sciences/microbiology/bacteriology
  • /medical and health sciences/basic medicine/immunology/immunotherapy
  • /medical and health sciences/health sciences/infectious disease/RNA virus/ebola

Call for proposal

H2020-Adhoc-2014-20
See other projects for this call

Funding Scheme

RIA - Research and Innovation action

Coordinator

INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT
Address
Boulevard De Dunkerque 44 Cs 90009
13572 Marseille
France
Activity type
Research Organisations
EU contribution
€ 360 895

Participants (8)

BEN-GURION UNIVERSITY OF THE NEGEV
Israel
EU contribution
€ 199 350
Address
.
84105 Beer Sheva
Activity type
Higher or Secondary Education Establishments
ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE LAZZARO SPALLANZANI-ISTITUTO DI RICOVERO E CURA A CARATTERE SCIENTIFICO
Italy
EU contribution
€ 52 700
Address
Via Portuense, 292
00149 Roma
Activity type
Research Organisations
INSTITUT PASTEUR
France
EU contribution
€ 127 075
Address
Rue Du Docteur Roux 25-28
75724 Paris Cedex 15
Activity type
Research Organisations
FABENTECH
France
EU contribution
€ 972 750
Address
4 Impasse Des Chartreux
69001 Lyon
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
UNIVERSITY OF MANITOBA
Canada
EU contribution
€ 0
Address
Administration Building Room 202
R3T 2N2 Manitoba
Activity type
Higher or Secondary Education Establishments
METABIOTA INC

Participation ended

United States
EU contribution
€ 100 000
Address
1 Sutter Suite 600
94104 San Francisco
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
ORION INTEGRATED BIOSCIENCES INC.
United States
EU contribution
€ 135 000
Address
265 Centre Ave
10805 New Rochelle
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
AK GROUP
France
EU contribution
€ 45 000
Address
41B Rue Dupetit Thouars
49000 Angers
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)